Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 2, 2026 166 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma March 12, 2021 Financial Navigation Can Reduce the Financial Toxicity of Cancer Care April 21, 2023 Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... November 20, 2019 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 Load more HOT NEWS Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer EMA Recommends Granting a Marketing Authorisation for Ivosidenib
